Liver Injury REMS Delays Agios’s Pyrukynd US FDA Approval In Thalassemia

Phase III Sickle Cell Data Due Before Year’s End

 
• By Mandy Jackson
  
Analysts expect Pyrukynd to receive FDA approval to treat thalassemia despite the action date delay (Shutterstock)

More from Rare Diseases

More from Scrip